Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 6/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | PGR | P06401 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.41 |
| ▸ | BLM | P54132 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9544639 | 0.82 | SHBG (0.65) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL3744059 | 0.80 | SHBG (0.68) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL3744063 | 0.80 | SHBG (0.68) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL13046030 | 0.79 | SRD5A2 (0.50) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL3744539 | 0.79 | SRD5A2 (0.50) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL14318945 | 0.79 | PGR (0.57) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL14285029 | 0.79 | PGR (0.57) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL9464776 | 0.77 | CYP17A1 (0.53) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL4214412 | 0.76 | PGR (0.62) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL3754967 | 0.75 | CYP19A1 (0.67) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | claimed |
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | disclosed |
| WO-2010066349-A1 | USE OF 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVES FOR MANUFACTURING A MEDICAMENT IN A SUSTAINED-RELEASE FORM FOR PARENTERAL USE, AND SUSTAINED-RELEASE MEDICAMENT CONTAINING 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVES FOR PARENTERAL USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | HSD17B11, HSD17B7, NR5A1 | SHBG 24/4885NR3C1 30/4885ALDH1A1 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.